# Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT07140328** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Chronic Obstructive Lung Disease (COLD)

## Interventions

- **DRUG:** HSK39004 Dry Powder Inhaler -0.75mg BID
- **DRUG:** HSK39004 Dry Powder Inhaler -1.5mg BID
- **DRUG:** HSK39004 Inhalation Suspension -3mg BID
- **DRUG:** HSK39004 Placebo

## Key facts

- **NCT ID:** NCT07140328
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-24
- **Primary completion:** 2025-07-10
- **Final completion:** 2026-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07140328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07140328, "Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07140328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*